Janux Therapeutics, Inc. Revenue from Contract with Customer, Including Assessed Tax
Janux Therapeutics, Inc. (JANX) reported Revenue from Contract with Customer, Including Assessed Tax of $10.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-08-06
- Janux Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-06-30 was $10.27M.
- Janux Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-03-31 was $3.73M.
- Janux Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-12-31 was $0.00.
- Janux Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $10.00M, a 2177.90% increase year-over-year.
- Janux Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2025 was $10.00M, a 5.55% decline from fiscal 2024.
- Janux Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2024 was $10.59M, a 30.99% increase from fiscal 2023.
- Janux Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2023 was $8.08M, a 6.14% decline from fiscal 2022.
- Janux Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2022 was $8.61M, a 136.79% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.27M 10-Q · filed 2026-08-06 | $14.00M 10-Q · filed 2026-08-06 | $14.00M derived: sum of 3 quarters · filed 2026-08-06 | $24.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.73M 10-Q · filed 2026-05-07 | $3.73M derived: sum of 2 quarters · filed 2026-05-07 | $13.73M derived: sum of 3 quarters · filed 2026-05-07 | $13.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $10.00M derived: sum of 2 quarters · filed 2026-02-26 | $10.00M derived: sum of 3 quarters · filed 2026-08-06 | $10.00M 10-K · filed 2026-02-26 |
| 2025-09-30 | $10.00M 10-Q · filed 2025-11-06 | $10.00M derived: sum of 2 quarters · filed 2026-08-06 | $10.00M 10-Q · filed 2025-11-06 | $10.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $439.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $439.00K derived: sum of 3 quarters · filed 2026-05-07 | $9.34M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $439.00K derived: sum of 2 quarters · filed 2026-02-26 | $9.34M derived: sum of 3 quarters · filed 2026-02-26 | $10.59M 10-K · filed 2026-02-26 |
| 2024-09-30 | $439.00K 10-Q · filed 2025-11-06 | $9.34M derived: sum of 2 quarters · filed 2025-11-06 | $10.59M 10-Q · filed 2025-11-06 | $13.05M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $8.90M 10-Q · filed 2025-08-07 | $10.15M 10-Q · filed 2025-08-07 | $12.61M derived: sum of 3 quarters · filed 2026-02-26 | $15.13M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $1.25M 10-Q · filed 2025-05-08 | $3.71M derived: sum of 2 quarters · filed 2026-02-26 | $6.23M derived: sum of 3 quarters · filed 2026-02-26 | $7.29M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.98M derived: sum of 2 quarters · filed 2026-02-26 | $6.04M derived: sum of 3 quarters · filed 2026-02-26 | $8.08M 10-K · filed 2026-02-26 |
| 2023-09-30 | $2.52M 10-Q · filed 2024-11-06 | $3.57M derived: sum of 2 quarters · filed 2024-11-06 | $5.62M 10-Q · filed 2024-11-06 | $8.47M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $1.06M 10-Q · filed 2024-08-07 | $3.10M 10-Q · filed 2024-08-07 | $5.95M derived: sum of 3 quarters · filed 2025-02-27 | $7.76M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $2.05M 10-Q · filed 2024-05-08 | $4.89M derived: sum of 2 quarters · filed 2025-02-27 | $6.71M derived: sum of 3 quarters · filed 2025-02-27 | $9.07M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $4.66M derived: sum of 2 quarters · filed 2025-02-27 | $7.02M derived: sum of 3 quarters · filed 2025-02-27 | $8.61M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.81M 10-Q · filed 2023-11-07 | $4.18M derived: sum of 2 quarters · filed 2023-11-07 | $5.77M 10-Q · filed 2023-11-07 | $7.38M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $2.37M 10-Q · filed 2023-08-08 | $3.95M 10-Q · filed 2023-08-08 | $5.57M derived: sum of 3 quarters · filed 2023-08-08 | $6.73M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $1.59M 10-Q · filed 2023-05-09 | $3.21M derived: sum of 2 quarters · filed 2023-05-09 | $4.36M derived: sum of 3 quarters · filed 2023-05-09 | $4.85M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $2.77M derived: sum of 2 quarters · filed 2023-03-10 | $3.26M derived: sum of 3 quarters · filed 2023-03-10 | $3.64M 10-K · filed 2023-03-10 |
| 2021-09-30 | $1.16M 10-Q · filed 2022-11-10 | $1.64M derived: sum of 2 quarters · filed 2022-11-10 | $2.02M 10-Q · filed 2022-11-10 | $2.02M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $482.00K 10-Q · filed 2022-08-09 | $862.00K 10-Q · filed 2022-08-09 | $862.00K derived: sum of 3 quarters · filed 2022-08-09 | $862.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $380.00K 10-Q · filed 2022-05-10 | $380.00K derived: sum of 2 quarters · filed 2022-05-10 | $380.00K derived: sum of 3 quarters · filed 2022-05-10 | $380.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $0.00 derived: sum of 2 quarters · filed 2022-03-18 | $0.00 derived: sum of 3 quarters · filed 2022-03-18 | $0.00 10-K · filed 2022-03-18 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-10 | $0.00 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |